High-dose DHA didn't protect memory or brain structure in a 2-year trial

What happened

A two-year randomized trial found that a high dose of purified DHA, an omega-3 fatty acid, did not improve thinking performance or protect the hippocampus (a memory-related brain region) in older adults at risk for dementia. The paper appeared in eBioMedicine on June 18, 2026 (PubMed record). It reached a wider audience in late October, as first reported by Healthline News (Healthline News).

One correction to the framing: this was not a classic fish-oil trial. Healthline quotes lead author Yassine saying the capsule was more than 90% DHA, about 1% EPA, and not made from fish. The university press release, by contrast, calls it fish oil (EurekAlert). The paper itself calls it DHA supplementation, so we do too.

What the trial actually found

Participants were 55 to 80, had no dementia, ate little DHA (under 200 mg a day) and had at least one dementia risk factor. They were randomized 1:1 to 2 g a day of DHA or placebo, with the split stratified by APOE ε4 status, a gene variant linked to higher Alzheimer's risk (PubMed).

The press release says 365 adults enrolled, with a mean age of 66 and 47% carrying APOE4. Healthline reports that 225 completed the trial. We could not check that completion figure against the paper's full text.

• The supplement got into the brain's environment. The paper says the trial met its primary objective: 2 g a day robustly raised the DHA-to-arachidonic-acid ratio in cerebrospinal fluid within 6 months, regardless of APOE ε4 status (eBioMedicine). The press release puts the average rise in spinal fluid DHA at 17%.
• The clinical outcomes were null. At 24 months, the authors report no benefit for hippocampal volume or cognitive performance.
• Blood levels climbed. Healthline reports the omega-3 index rose from 4.9% to 11% over two years, a figure we could not verify in the paper.

The hippocampal numbers in the abstract excerpt we saw had no units or p-values, and the direction differed between the left and right sides. We are not leaning on them. The authors' conclusion is that broad supplementation alone is not enough to change cognitive or structural outcomes in a relatively healthy population over two years.

What it does not show

• It does not cover fish oil generally. This was one high-dose, near-pure DHA product, so it says nothing about EPA-containing fish oil, lower doses or food-based omega-3.
• Two years may be too short. An outside expert told Healthline that Alzheimer's develops over decades. Yassine says researchers are split on whether the result means supplements fail alone or the trial needed longer follow-up or sicker participants.
• The group was relatively healthy, ate little DHA at baseline and came from a single site. The authors say the result applies to that population and timeframe. People who already get plenty of omega-3 may respond differently.
• Attrition matters. If Healthline's 225-of-365 figure is right, about 38% did not finish. The hippocampal analyses in the abstract reportedly use roughly 170 to 177 people per arm, which we could not reconcile with Healthline's 225-completer figure.
• Cognition was not the headline endpoint. The paper presents brain delivery as the primary objective, and we could not confirm how the cognitive and MRI outcomes were pre-specified or powered.

We also could not retrieve the full text, trial registration details, effect sizes or adverse events. Treat this as a clear signal, not a final word.

What it means for you

If you take omega-3s mainly to protect your memory, this trial gives you little reason to expect it. Even with DHA measurably rising in spinal fluid, the brain outcomes did not move. More of the nutrient in the right place did not translate into a visible benefit.

That is not an argument to stop eating fish. The National Center for Complementary and Integrative Health (NCCIH) says the most consistent positive findings involve omega-3 intake, often measured as fish eaten, and that direct evidence supplements can prevent Alzheimer's or other dementias is lacking (NCCIH, NCCIH).

Both the press release and Healthline point to exercise, sleep and a Mediterranean-style diet as the better-supported approach. The press release calls that out of scope for the study, so it is the researchers' view, not a trial result. Healthline also cites a CDC survey in which 21.8% of US adults 60 and older took an omega-3 supplement in a 30-day window (2017–2018). We did not check the CDC data ourselves.

Context: a pattern, with some mixed signals

This result fits earlier work. A large NIH trial of about 4,000 people followed for 5 years found omega-3 supplements did not slow cognitive decline (EurekAlert). A 2012 Cochrane review found no benefit for cognitive function in cognitively healthy older people, though it noted direct evidence on dementia was lacking and called for longer studies (PubMed).

For people who already have Alzheimer's, a JAMA trial of DHA found no overall treatment effect. It saw a possible benefit only in an exploratory subgroup without APOE ε4, which the authors read cautiously (JAMA).

The picture is not uniformly null. NCCIH cites a 2022 review of 33 studies suggesting dietary and supplemental omega-3s may be protective in healthy people, while noting small samples, varying doses and short durations (NCCIH). An overview of systematic reviews includes some that report small positive effects (PMC).

What this trial adds is a cleaner answer to an old question. The same group's 2020 trial looked at brain delivery of DHA over 6 months (PMC). The authors say the new one shows DHA reaches the brain without changing outcomes, and they suggest future work focus on brain DHA metabolism rather than more supplementation trials.